A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML (Blasts < 30%) in Relapse After Allohematopoietic Stem Cell Transplantation
Latest Information Update: 07 May 2025
At a glance
- Drugs Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Apr 2025 Planned End Date changed from 1 Mar 2026 to 1 Sep 2027.
- 27 Apr 2025 Planned primary completion date changed from 1 Sep 2025 to 1 Mar 2026.
- 02 Apr 2024 Planned number of patients changed from 48 to 55.